

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

1.1 Product identifier

FARXIGA TABLETS

Details of the supplier of the safety data sheet

: ASTRAZENECA PTY LTD EmergencyTelephone
PO Box 131 +44 (0) 1235 239 670
66 Talavera Rd, North Ryde
NSW 2113
AUSTRALIA
+61 2 9978 3500

SafetyDataSheets.AlderleyPark@astrazeneca.com

Alternative Names

Forxiga tablets
Dapagliflozin tablets 2,5 mg, 5 mg and 10 mg
CAS No. : Not applicable

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Substance/Mixture : Treatment of diabetes

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Kidney, Bone)

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360 May damage fertility or the unborn child.
H362 May cause harm to breast-fed children.
H373 May cause damage to organs (Kidney, Bone) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P264 Wash skin thoroughly after handling.
P281 Use personal protective equipment as required.

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
 Date of first issue: 24.02.2017

Response:

P308 + P313 IF exposed or concerned: Get medical advice/attention.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Hazardous components which must be listed on the label:

Dapagliflozin

Other hazards which do not result in classification

May cause hypoglycemia.

May cause eye irritation.

The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Hazardous components

Chemical name	CAS-No.	Concentration (% w/w)
Celluloses	9004-34-6	60 -70
Dapagliflozin	960404-48-2	2 -5

SECTION 4. FIRST AID MEASURES

- If inhaled : Remove patient from exposure.
Obtain medical attention if ill effects occur.
- In case of skin contact : Wash skin with soap and water.
- In case of eye contact : Irrigate with eyewash solution or clean water, holding the eyelids apart, for at least 10 minutes.
Obtain medical attention if ill effects remain.
- If swallowed : Wash out mouth with water and give 200-300ml of water to drink.
Obtain medical attention if ill effects occur.
Do NOT induce vomiting as a First-Aid measure.
- Most important symptoms and effects, both acute and delayed : Refer to sections 2 and 11
May damage fertility or the unborn child.
May cause harm to breast-fed children.
May cause damage to organs through prolonged or repeated exposure if swallowed.
- Notes to physician : Symptomatic treatment and supportive therapy as indicated.
For further information consult the prescribing information.

SECTION 5. FIREFIGHTING MEASURES

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
 Date of first issue: 24.02.2017

- Suitable extinguishing media : water spray, foam, dry powder or CO₂.
- Unsuitable extinguishing media : Avoid high pressure media which could cause the formation of a potentially explosible dust-air mixture.
Do not use water jet.
- Specific hazards during firefighting : If involved in a fire, it may burn and emit noxious and toxic fumes.
- Special protective equipment for firefighters : A self contained breathing apparatus and suitable protective clothing should be worn in fire conditions.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Ensure suitable personal protection during removal of spillages.
Avoid dispersal of dust in the air.
See Section 8.
- Environmental precautions : Prevent entry into drains, sewers or watercourses.
- Methods and materials for containment and cleaning up : Avoid dust generation.
Transfer spilled tablets to a suitable container for disposal.
Wash the spillage area with water.

SECTION 7. HANDLING AND STORAGE

- Advice on safe handling : Avoid contact with skin and eyes.
Avoid breathing dust.
Minimize dust generation and accumulation.
The product may form flammable dust clouds in air, if dust from crushed tablets is allowed to accumulate.
- Conditions for safe storage : Keep container tightly closed.
Protect from light.
Keep away from heat, sources of ignition and direct sunlight.
- Recommended storage temperature : 15 - 25 °C

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Celluloses	9004-34-6	TWA	10 mg/m ³	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m ³	ACGIH
Dapagliflozin	960404-48-2	TWA	0.01 mg/m ³	COM

Version	Revision Date:	SDS Number:	Date of last issue: 24.05.2017
3.2	08.02.2018	20513	Date of first issue: 24.02.2017

Engineering measures : The specific controls will depend on local circumstances and should be based on the risk assessment. Appropriate controls to reduce exposure may include engineering controls, for example ventilation, procedural controls and the use of personal protection equipment.

Prevent entry into drains, sewers or watercourses.

Personal protective equipment

Respiratory protection : Use an air fed hood if the risk assessment does not support the selection of other protection.

Eye protection : Use safety glasses to protect against direct contact with the substance if the risk assessment does not support the selection of other protection.

Skin and body protection : Use impervious clothing to protect against direct contact with the product or for repeated, excessive handling use full chemical protective suit if the risk assessment does not support the selection of other protection. Use impervious protective gloves to protect against direct contact with the product. If the product is dissolved or wetted use a glove material that is resistant to the solvent/liquid.

Protective measures : Decisions about whether the use of personal protective equipment (PPE) is appropriate as part of the control strategy should be based on the workplace risk assessment and should take account of local legislative requirements for selection and use. There are multiple factors that will affect the specific requirements such as amount and concentration of the material, duration of exposure, frequency of exposure, external environmental conditions, the task, the user etc. All the information above should not be used in isolation and should be considered in the context of the workplace risk assessment on a case by case basis.

The recommended personal protective equipment (PPE) is based on preventing the potential adverse health effects from exposure to the active pharmaceutical ingredient (API). The risk of exposure to the API in the formulation/product needs to be taken into consideration.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : film-coated tablets

Colour : yellow

Odour : No data available

Odour Threshold : No data available

SAFETY DATA SHEET



Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

pH : No data available

Melting point/range : No data available

Initial boiling point and boiling range : Not applicable

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Solubility(ies)

 Water solubility : No data available

 Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

 Viscosity, dynamic : Not applicable

 Viscosity, kinematic : Not applicable

Explosive properties : No data available

Oxidizing properties : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No known reactivity hazard under normal conditions.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : None known

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

Conditions to avoid : No conditions producing hazardous situations known.

Incompatible materials : None known.

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

11.1 Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Remarks: Low acute oral toxicity.

Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Dapagliflozin:

Acute oral toxicity : Evident toxicity with mortality in rats at a dose of: 750 mg/kg
Assessment: The component/mixture is moderately toxic after single ingestion.

Acute inhalation toxicity : Remarks: No information available on acute toxicity.
May cause effects as described under repeated exposure.(STOT)

Acute dermal toxicity : Remarks: No data available

11.2 Skin corrosion/irritation

Not classified based on available information.

Components:

Dapagliflozin:

Remarks: Non-irritant.

11.3 Serious eye damage/eye irritation

Not classified based on available information.

Components:

Dapagliflozin:

Result: Eye irritation

11.4 Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

Respiratory sensitisation

Not classified based on available information.

Components:

Dapagliflozin:

Remarks: It is not a skin sensitiser in vivo.
Unlikely to cause skin sensitisation.

Chronic toxicity

11.5 Germ cell mutagenicity

Not classified based on available information.

Components:

Dapagliflozin:

Germ cell mutagenicity - Assessment : The substance is not considered to be genotoxic.

11.6 Carcinogenicity

Not classified based on available information.

Components:

Dapagliflozin:

Carcinogenicity - Assessment : Studies in animals have shown that chronic exposures produce no carcinogenic effects.

11.7 Reproductive toxicity

May damage fertility or the unborn child.
May cause harm to breast-fed children.

Components:

Dapagliflozin:

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.
Effects on or via lactation

11.8 STOT - single exposure

Not classified based on available information.

Components:

Dapagliflozin:

Remarks: May cause effects as described under repeated exposure.(STOT)

11.9 STOT - repeated exposure

May cause damage to organs (Kidney, Bone) through prolonged or repeated exposure if swallowed.

Version	Revision Date:	SDS Number:	Date of last issue: 24.05.2017
3.2	08.02.2018	20513	Date of first issue: 24.02.2017

Components:**Dapagliflozin:**

Exposure routes: Oral

Target Organs: Kidney, Bone

Assessment: Causes damage to organs through prolonged or repeated exposure.

Remarks: These effects are derived from studies in animals.

Remarks: Repeated exposure may cause diarrhea, nausea, gastrointestinal discomfort, weakness, headache, dizziness, sweating, paleness, rash, dermatitis, swelling, blurred vision, abdominal pain, flank pain, changes in clinical chemistry parameters, and lowered blood pressure.

Increased risk of urinary tract infection and fungal infection.

May cause hypoglycemia.

It may produce diuretic effects.

11.10 Aspiration toxicity

Not classified based on available information.

Components:**Dapagliflozin:**

No data available

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Dapagliflozin:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 120 mg/l
Exposure time: 48 H
Method: OECD Test Guideline 202

Toxicity to algae : ErC50 (green algae): 120 mg/l
Exposure time: 72 H

NOEC (green algae): 37 mg/l
Exposure time: 72 H
Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 1 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210
Remarks: Highest concentration tested (no effects).

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 10 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms : (NOEC) Respiration inhibition (Sewage sludge organisms): 200 mg/l
Exposure time: 3 H

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:

Dapagliflozin:

Biodegradability : Biodegradation: 11 %
Method: OECD Test Guideline 301F
Remarks: Not rapidly degradable.
The substance is not significantly hydrolyzed in water.

Bioaccumulative potential

Components:

Dapagliflozin:

Bioaccumulation : Remarks: The substance has low potential for bioaccumulation.

Mobility in soil

Components:

Dapagliflozin:

Mobility : Remarks: Water solubility \geq 1 mg/l.

Distribution among environmental compartments : Remarks: No information available.

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Disposal should be in accordance with local, state or national legislation.
Waste, even small quantities, should never be poured down drains, sewers or water courses.
Normal waste disposal is via incineration operated by an accredited disposal contractor.

Contaminated packaging : Empty container will retain residue. Observe all hazard precautions.

SECTION 14. TRANSPORT INFORMATION

Not classified as dangerous in the meaning of transport regulations.

Version 3.2 Revision Date: 08.02.2018 SDS Number: 20513 Date of last issue: 24.05.2017
Date of first issue: 24.02.2017

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

In order to comply with legal duties it is necessary to consult local and national legislation.

Standard for the Uniform Scheduling of Medicines and Poisons : No poison schedule number allocated

Prohibition/Licensing Requirements : There is no applicable prohibition or notification/licensing requirements, including for carcinogens under Commonwealth, State or Territory legislation.

The components of this product are reported in the following inventories:

REACH : Not listed

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Dapagliflozin 960404-48-2

AICS : Not listed

ENCS : Not listed

ISHL : Not listed

IECSC : Not listed

TCSI : Not listed

TSCA : Not On TSCA Inventory

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; CPR - Controlled Products Regulations; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan);

SAFETY DATA SHEET



Version	Revision Date:	SDS Number:	Date of last issue: 24.05.2017
3.2	08.02.2018	20513	Date of first issue: 24.02.2017

ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Further information

Revision Date : 08.02.2018

Other information : Minor changes:, 1, 3, 9, 11, 12, 15, 16

Date format : dd.mm.yyyy

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.

ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

AU / EN